|
市場調査レポート
商品コード
1245681
分析機器の世界市場の規模、シェア、産業動向分析レポート:製品別(機器、ソフトウェア、サービス)、技術別、用途別、地域別展望と予測、2022年~2028年Global Analytical Instrumentation Market Size, Share & Industry Trends Analysis Report By Product (Instruments, Software and Services), By Technology, By Application, By Regional Outlook and Forecast, 2022 - 2028 |
||||||
分析機器の世界市場の規模、シェア、産業動向分析レポート:製品別(機器、ソフトウェア、サービス)、技術別、用途別、地域別展望と予測、2022年~2028年 |
出版日: 2023年02月28日
発行: KBV Research
ページ情報: 英文 283 Pages
納期: 即納可能
|
分析機器の世界市場規模は、2028年までに664億米ドルに達すると予測され、予測期間中にCAGR 4.0%の市場成長率で上昇すると予想されています。
また、企業は拡大する需要を満たすために革新的な技術を開発し、未開拓の市場の可能性を開拓しており、これは分析機器の技術的進歩によって推進されています。さらに、精密医療の進展に伴い、分析機器ソリューションの利用が増加すると予想されています。病気を特定し、カスタマイズされた治療法を作るために、精密医療では次世代シーケンサー、分子イメージング、分子動力学、分子診断に分析機器を活用します。
例えば、分子診断では、患者のバイオマーカーを分析するために、ゲノム配列の解析が行われます。このような検査をさまざまな分析ツールで実施することで、最適な治療方針に関する知識を得たり、特定の患者に最も適した治療法を予測したりすることもできます。さらに、医薬品開発プロセスでは、顕微鏡や低温電子顕微鏡などの技術を使って、タンパク質などの生物体の3D構造を広く研究しています。
COVID-19の影響度分析
COVID-19の大流行により、熱分析機器、分光器、クロマトグラフィー関連機器などの分析機器事業が縮小しました。これは、厳しい規制の実施や供給網の遮断、その間の臨床試験の減少がもたらしたものです。しかし、パンデミックにより、2021年にはPCR、マイクロアレイ、シーケンサー技術関連機器の需要が大幅に増加しました。この間、増加するCOVID-19症例に対応するため、いくつかの新規PCR製品が導入されました。商品の需要の偏りと共に、商品の配送が遅れるなどの問題があり、分析機器業界のサプライチェーンを阻害しました。
市場成長要因
高精度医療の開発が急速に進展
このため、精密診断や治療法の大幅な改善、次世代シーケンサー(NGS)や大規模ゲノムデータなどの開発が推進されています。さらに、遺伝子治療や、がん、結核、アルツハイマー病などの病気を治療するための精密医薬品の開発にも大きな進展がありました。その結果、より多くの製薬会社やバイオテクノロジー企業がこの市場に参入し始めています。したがって、分析機器市場の成長は、個別化された医薬品や治療法を提供する精密医療の台頭によって後押しされているのです。
水処理・廃水処理における分析機器の使用量の増加
水や排水には、クロマトグラフィーのような多くのプロセスが存在します。そのため、クロマトグラフィー分野の発展は、ビッグデータや人工知能(AI)のような最先端技術の取り込みによって推進されています。こうした技術は、クロマトグラフィー中に発生する大量のデータにより、データの分類を自動化し、定量結果の信頼性を高めると予想されます。したがって、主に水・廃水処理の特性やパラメータを評価するためのさまざまな研究開発活動における分析機器の要件が、市場の成長を加速しています。
市場抑制要因
分析機器を操作する熟練した専門家の不足
分析機器は技術の向上により複雑化し、熟練したスタッフが効率よく扱うことが必要になっています。また、検査施設を設置するためのインフラが整っていないことも大きな障害となっています。製造業は細分化され、小規模な企業が多いため、多くの途上国では、こうした企業からのサンプル採取が困難な場合があります。制度的な協力の欠如と設備不足は、他の2つの重要な問題です。その結果、有能な専門家の不足が、エンドユーザーによる検査機器や消耗品の普及を制限し、市場の成長を鈍らせることになるでしょう。
製品の展望
製品に基づき、分析機器市場は、機器、サービス、ソフトウェアに分類されます。2021年の分析機器市場では、ソフトウェア分野がかなりの成長率を確保しました。ソフトウェアは、学術研究や臨床診断などさまざまな場面で、分析作業におけるデータ処理や結果の解釈のために頻繁に利用されています。例えば、フローサイトメトリーソフトウェアの助けを借りて、データの取得と制御が行われ、その後、結果の統計分析が行われます。予測期間中、このようなソフトウェアの能力が、セグメントの拡大を促進すると予想されます。
技術展望
技術別に見ると、分析機器市場は、ポリメラーゼ連鎖反応、分光法、顕微鏡、クロマトグラフィー、フローサイトメトリー、シーケンサー、マイクロアレイ、その他に分けられます。2021年の分析機器市場では、クロマトグラフィー部門が大きな収益シェアを記録しました。ライフサイエンス、製薬、その他の分野における多様な用途が、このセグメントの上昇の主な原因となっています。クロマトグラフィーの3つのタイプは、ガス、液体、およびイオンです。複雑なプロテオミクス研究は、液体クロマトグラフィーを使って発見されます。イオンクロマトグラフィーは、環境試験など品質管理が必要な分野で採用されています。
用途の展望
用途に基づき、分析機器市場はライフサイエンス研究開発、臨床&診断分析、飲食品分析、法医学分析、環境試験、その他に分類されます。2021年の分析機器市場では、臨床&診断分析分野がかなりの収益シェアを獲得しました。がんや慢性疾患の有病率の上昇により、診断検査に対する強い需要があり、臨床検査用のフローサイトメーターのような分析機器グッズの需要を促進すると予測されます。さらに、臨床検査室向けの新規分析機器の承認と導入が、セグメントの成長を加速させると予測されます。これにより、サンプルを迅速、安価、かつ正確に特定することが可能になります。
地域別展望
地域別では、分析機器市場は、北米、欧州、アジア太平洋、LAMEAで分析されます。北米セグメントは、2021年の分析機器市場で最も高い収益シェアを示しました。このかなりの市場シェアは、この地域の確立された製薬部門とヘルスケアシステムによるものであり、臨床および研究用途の分析機器に対するかなりの需要を生み出しています。また、さまざまな疾患に対するワクチンや医薬品の開発を目的とした研究開発プロジェクトの数が多いことや、がん研究に対する官民の支援が充実していることも、分析機器や計測器の必要性に拍車をかけています。
市場参入企業がとる主な戦略は、「買収」です。カーディナルマトリックスに掲載された分析によると、F. Hoffmann-La Roche Ltd.、Thermo Fisher Scientific Inc.、Danaher Corporationが分析機器市場の先行者となっています。Bio-Rad Laboratories, Inc.、Carl Zeiss AG、Agilent Technologies, Inc.などの企業は、分析機器市場における主要な革新者の一人です。
List of Figures
The Global Analytical Instrumentation Market size is expected to reach $66.4 billion by 2028, rising at a market growth of 4.0% CAGR during the forecast period.
Analytical instrumentation is laboratory equipment used to investigate the separation, identification, and quantification of chemical components in both natural and synthetic materials. These analytical tools are employed to gather quantitative and qualitative data regarding the existence of a number of components in a particular sample. These tools are also used in a wide range of clinical diagnostic procedures as well as life sciences research to create new therapeutic and diagnostic products.
Pharmaceutical and biotechnology sectors have emerged as the leading end-users of analytical equipment due to their significant usage of these tools throughout the drug development process as a result of their vast R&D activities. Pharmaceutical enterprises are actively engaging and investing in R&D for the development of advanced and efficient products. Consequently, increased R&D investments and instrument adoption rates are likely to drive market growth.
In addition, enterprises are developing innovative technologies to fulfil expanding demand and exploit untapped market potential, which is being driven by the technological advancement of analytical instrumentation. Additionally, the use of analytical instrumentation solutions is anticipated to increase due to the growing development of precision medicine. In order to identify illnesses and create customized therapies, precision medicine utilizes analytical instrumentation for next-generation sequencing, molecular imaging, molecular dynamics, and molecular diagnostics.
For example, genomic sequencing is used in molecular diagnostics to analyze a patient's biomarkers. These tests carried out with different analytical tools, provide knowledge on the optimal course of action or even forecast the treatments that are most appropriate for a specific patient. Additionally, the 3D structures of biological organisms like proteins are widely studied using microscopes and techniques like cryogenic electron microscopy in the drug development process.
COVID-19 Impact Analysis
The COVID-19 pandemic caused a decline in the business of analytical instruments, including heat analyzers, spectroscopy, and chromatography-related equipment. This was brought on by the implementation of severe lockdown regulations, the interruption of supply networks, and a decline in clinical trial activity during that time. However, the pandemic caused a huge increase in demand for PCR, microarray, and sequencing technology-related instruments in 2021. Several novel PCR products were introduced during this time to address the rising COVID-19 cases. Problems like late product delivery along with an uneven demand for goods, hampered the supply chain of the analytical instruments industry.
Market Growth Factors
Rapid advancement in the development of precision medicine
This has propelled significant improvements in precision diagnoses and therapeutics as well as developments like next generation sequencing (NGS) and large genomic data. Additionally, there have been significant developments in gene therapy and the creation of precision medicines to treat ailments like cancer, TB, and Alzheimer's. As a result, more pharmaceutical and biotech businesses are starting to enter this market. Therefore, the growth of the analytical instrumentation market is being booted by the rise of precision medicine, providing individualized medicines and treatments.
Increasing usage of analytical instrumentation in water and wastewater treatment
Water and wastewater involve many processes, like chromatography. Therefore, the chromatography sector's development is driven by the incorporation of cutting-edge technologies like Big Data and artificial intelligence (AI). Such technologies are anticipated to automate the categorization of data and enhance the reliability of quantitative results due to the large amount of data generated during chromatography. Therefore, the requirement of analytical instrumentation in different R&D activities mainly to evaluate the characteristics and parameters of water & wastewater treatment is accelerating the market growth.
Market Restraining Factors
Dearth of skilled professionals to operate analytical equipment
The complexity of analytical instruments has significantly risen due to technological improvements, making it necessary to have a skilled crew handle them efficiently. Another significant obstacle is the lack of supporting infrastructure to establish testing facilities. Due to the fragmentation and predominance of small businesses in the manufacturing industry, sample collection from these businesses might be difficult for testing service providers in many developing nations. Lack of institutional cooperation and equipment shortage are two other significant problems. As a result, the lack of qualified specialists will probably limit how widely laboratory instruments and consumables are used by end users, thus slowing the market's growth.
Product Outlook
Based on product, the analytical instrumentation market is categorized into instruments, services, and software. The software segment procured a considerable growth rate in the analytical instrumentation market in 2021. Software is frequently utilized in various contexts, including academic research and clinical diagnosis, for data processing and result interpretation in analytical operations. For instance, with the help of flow cytometry software data is acquired & controlled, after which the results are statistical analysis is done. Over the course of the projected period, such software abilities are expected to fuel segment expansion.
Technology Outlook
On the basis of technology, the analytical instrumentation market is divided into polymerase chain reaction, spectroscopy, microscopy, chromatography, flow cytometry, sequencing, microarray, and others. The chromatography segment recorded a significant revenue share in the analytical instrumentation market in 2021. The diverse applications in life science, pharmaceutical, and other areas are mostly accountable for the segment's rise. The three types of chromatography are gas, liquid, and ion. Complex proteomic studies are discovered using liquid chromatography. Ion chromatography techniques are employed in fields where quality control is necessary like environmental testing.
Application Outlook
Based on application, the analytical instrumentation market is segmented into life sciences research & development, clinical & diagnostic analysis, food & beverage analysis, forensic analysis, environmental testing, and others. The clinical & diagnostic analysis segment acquired a substantial revenue share in the analytical instrumentation market in 2021. There is a strong demand for diagnostic tests due to the rising prevalence of cancer and chronic diseases, which is projected to fuel demand for analytical equipment goods like flow cytometers for clinical testing. Additionally, it is projected that the approval and introduction of novel analytical apparatus for clinical laboratories will accelerate segment growth. This makes it possible to identify samples quickly, cheaply, and accurately.
Regional Outlook
On the basis of region, the analytical instrumentation market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America segment witnessed the highest revenue share in the analytical instrumentation market in 2021. This considerable market share can be due to the region's established pharmaceutical sector and healthcare system, which have generated a sizable demand for analytical instruments for clinical and research applications. The need for analytical instruments and instrumentation have also been spurred by high number of R&D projects that aim to develop vaccines and medicines for different diseases and by engaging more public-private support in cancer research.
The major strategies followed by the market participants are Acquisition. Based on the Analysis presented in the Cardinal matrix; F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc. and Danaher Corporation are the forerunners in the Analytical Instrumentation Market. Companies such as Bio-Rad Laboratories, Inc., Carl Zeiss AG, and Agilent Technologies, Inc. are some of the key innovators in Analytical Instrumentation Market.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Thermo Fisher Scientific, Inc., Agilent Technologies, Inc., PerkinElmer, Inc., Illumina, Inc., Bio-Rad Laboratories, Inc., Carl Zeiss AG, Danaher Corporation, Bruker Corporation, F. Hoffmann-La Roche Ltd., and Mettler-Toledo International, Inc.
Recent Strategies Deployed in Analytical Instrumentation Market
Mergers & Acquisition
Jan-2023: Thermo Fisher Scientific Inc. took over The Binding Site Group, a global leader in specialty diagnostics. Through this acquisition, Thermo Fisher Scientific Inc. would be able to extend its current specialty diagnostics portfolio along with pioneering innovation in monitoring and diagnostics for numerous myelomas.
Jan-2023: Carl Zeiss AG took over LENSO Sp. Z.o.o, a company that works in the field of servicing manufacturing companies in the field of precise industrial metrology. Through this acquisition, Carl Zeiss AG would be able to provide a fluent and combined experience to get the finest measuring solutions for the specific applications for its customers.
Mar-2022: Thermo Fisher Scientific, Inc., acquired Max Analytical Technologies, a producer of FTIR-based gas analysis solutions for process monitoring, source testing, and ambient air monitoring. Through this acquisition, Thermo Fisher Scientific, Inc., would be able to complete and extend its Software, FTIR instrument, and service offerings. Moreover, this acquisition would aid Thermo Fisher Scientific, Inc., to grow the range of vibrational spectroscopy services and solutions across a spectrum of market segments.
Feb-2022: Agilent Technologies Inc., took over Virtual Control's Advanced Artificial Intelligence (AI) Technology. Through this acquisition, Agilent Technologies Inc. would be able to combine the software into its industry-leading gas mass spectrometry and chromatography (GS/MS) platforms to enhance the efficiency, accuracy, and productivity of high-throughput labs.
Jun-2020: Illumina, Inc. took over BlueBee, a cloud-based software company that provides genomics analysis solutions for research and clinical customers. Through this acquisition, Illumina, Inc. would be able to combine BlueBee's abilities into its cloud portfolio which would further provide users the flexibility to operate their custom analyses or access industry-leading options. Moreover, this would lead to the most efficient, extensible, and scalable genomic analysis solutions for both translational and clinical research use cases.
Apr-2020: Bio-Rad Laboratories, Inc. took over Celsee, Inc., a company that offers instruments and consumables for the isolation, detection, and analysis of single cells. Through this acquisition, Bio-Rad Laboratories, Inc. would expand its spread into the fast-growing world of single-cell analysis and precision medicine, both of which contribute to an improved understanding of diagnosis, treatment, and disease with the help of Celsee's technologies and products.
Aug-2019: Agilent Technologies, Inc., took over BioTek Instruments, a global leader in the design, manufacture, and distribution of innovative life science instrumentation. Through this acquisition, Agilent Technologies, Inc. would be able to extend its growing existence and expertise in cell analysis. Moreover, this would strengthen the company's standing in the growing and immense immunotherapy and immuno-oncology areas.
May-2018: PerkinElmer, Inc. took over Shanghai Spectrum Instruments Co., Ltd, one of the leading manufacturers of analytical instruments in China. Through this acquisition, PerkinElmer, Inc. intends to construct SSI's manufacturing capabilities and R&D in China to supply continuous software and hardware creations for its customers and support China's purpose of strengthening local manufacturing.
Mar-2018: Agilent Technologies Inc., acquired Advanced Analytical Technologies, Inc., a provider of capillary electrophoresis-based (CE) solutions for the fully-automated analysis of a range of molecules. Through this acquisition, Agilent Technologies Inc. would be able to improve its current technology and expertise while providing customers with a better complete group of solutions.
Product Launch and Product Expansions
Sep-2022: Perkinelmer, Inc. launched Dubbed Cellaca PLX Image Cytometry System. The new platform enables researchers to assess various critical quality attributes of cell samples, including quality, quantity, and identity of cells, in one automated workflow.
Sep-2022: PerkinElmer, Inc. unveiled Cellaca PLX Image Cytometry System. This new product allows researchers to evaluate multiple Critical Quality Attributes (CQAs) of cell samples in a single automated workflow, including Quality, Quantity, and Cell Identity. Additionally, the Cellaca PLX integrates superior image cytometer software, hardware, trackable data, and validated consumables reporting all in one system without needing intense training requirements or complex calibration procedures.
Jun-2022: Agilent Technologies, Inc., launched new LC/MS and GC/MS quadrupole mass spectrometers. The new GC/TQ and LC/TQ products propose built-in instrument intelligence to streamline lab operations. Additionally, the new GC/TQ and GC/SQ products with the HydroInert source aid customers overcome key performance challenges with hydrogen carrier gas.
Feb-2022: Thermo Fisher Scientific Inc., launched a new portfolio of Chromatography and Mass Spectrometry consumables. This new product is crafted to fulfill higher performance needs while staying economical. Additionally, a new collection of vials, kits, caps, inserts, mats, and well plates would further enhance sample security and analytical performance for mass spectrometry and chromatography users in research and routine laboratories.
Mar-2020: Thermo Fisher Scientific Inc., unveiled the new Thermo Scientific Vanquish Core HPLC Systems. This new product would be able to extend the performance of the Vanquish platform to deliver a productivity-enhancing solution for routine laboratories.
Partnerships, Collaborations & Agreements
Jun-2021: Bio-Rad Laboratories, Inc. partnered with Seegene, Inc., a global leader in multiplex molecular diagnostics. Through this partnership, Bio-Rad Laboratories, Inc. would be able to use the diagnostic tests offered by Seegene, Inc. for its CFX96™ Dx Real-Time PCR System for clearance from The U.S. Food & Drug Administration (FDA) and U.S. markets pending clinical development.
Sep-2019: Thermo Fisher Scientific, Inc., came into collaboration with Cedars-Sinai, a leading nonprofit academic healthcare organization. Under this collaboration, Thermo Fisher Scientific, Inc., would target to deliver clinical research laboratories with sensitive and specific LC-MS-based workflows that would further provide improved confidence in data while witnessing and examining novel or comprehended protein-based biomarkers within biological matrices.
Market Segments covered in the Report:
By Product
By Technology
by Application
By Geography
Companies Profiled
Unique Offerings from KBV Research